Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Six patients with primary biliary cirrhosis (PBC) were treated with a daily oral dose of 600 mg rifampicin for 2 weeks to induce the hepatic metabolism of drugs and bile acids. On rifampicin 5 of 6 patients experienced a pronounced decrease of their pruritus. In all patients the oxidative cytochrome P-450 dependent drug metabolism was induced as shown by an increase of antipyrine-clearance from 36.3 +/- 8.8 to 80.6 +/- 20.1 ml/min and an enhanced urinary excretion of 6-beta-hydroxycortisol from 454 +/- 1.99 to 1607 +/- 362 micrograms/24 h. Furthermore, in all 6 patients the serum alkaline phosphatase declined. In the 3 cholestatic patients (bilirubin greater than 1.0 mg/dl) the serum concentration of total and conjugated bile acids was strikingly reduced. Thus, rifampicin is an inducer of hepatic metabolism in PBC-patients, ameliorates the pruritus and can lower serum concentrations of alkaline phosphatase and bile acids.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Clinical Pharmacokinetics of Rifampicin
Acocella, G. (1978) · Clinical Pharmacokinetics · doi:10.2165/00003088-197803020-00002 · Cited by 405
A simple and sensitive assay of total serum bile acids
Mashige, F., Imai, K., & Osuga, T. (1976) · Clinica Chimica Acta · doi:10.1016/0009-8981(76)90007-3 · Cited by 329
Metabolism and Pharmacokinetics of the Antibiotic Rifampin
Kenny, M. T., & Strates, B. S. (1981) · Drug Metabolism Reviews · doi:10.3109/03602538109011084 · Cited by 136
Phenobarbital Effects in Cholestatic Liver Disease
BLOOMER, J. R., & BOYER, J. L. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-3-310 · Cited by 120 · cited 1×
“Phenobarbital is effective in reducing serum bile acid concentration and pruritus in some patients with chronic cholestatic liver disease, such as primary biliary cirrhosis (PBC), biliary atresia and sclerosing cholangitis (Bloomer and Boyer 1975; Stellard et al. 1979).”
BackgroundDanhof, M., & Breimer, D. D. (1979) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1979.tb01040.x · Cited by 74
Enzyme-inducing drug combinations and their effects on liver microsomal enzyme activity in man
Ohnhaus, E. E., Gerber-Taras, E., & Park, B. K. (1983) · European Journal of Clinical Pharmacology · doi:10.1007/bf00613826 · Cited by 36
Self-citationPhenobarbital-induced alterations of bile acid metabolism in cases of intrahepatic cholestasis
Back, P. (1982) · Journal of Molecular Medicine · doi:10.1007/bf01724209 · Cited by 27
Enzyme induction and renal function in man.
Ohnhaus, E. E., Martin, J. V., Kinser, J. A., & Colombo, J. (1977) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1977.tb00663.x · Cited by 19
Self-citationEffects of rifampin on biliary lipids in humans
von Bergmann, K., Fierer, J., Mok, H. Y. I., & Grundy, S. M. (1981) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.19.2.342 · Cited by 8
Stellaard, F., Bolt, M. G., Jl, B., & Pd, K. (1979) · PubMed · Cited by 6
Cited by
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
“Rifampicin, a pregnane X receptor agonist, has been used to successfully treat pruritus in patients with PBC in multiple small clinical trials at doses ranging from 150 mg daily to 300 mg twice daily.(193-196) Two meta-analyses have reported that rifampicin administration is associated with relief of pruritus in chole…”
Intrahepatic cholestasis of pregnancy
Geenes, V., & Williamson, C. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.2049 · Cited by 675
Watkins, P. B., Murray, S. A., Winkelman, L. G., Heuman, D. M., Wrighton, S. A., & Guzelian, P. S. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113933 · Cited by 345
MARSCHALL, H., WAGNER, M., ZOLLNER, G., FICKERT, P., DICZFALUSY, U., GUMHOLD, J., SILBERT, D., FUCHSBICHLER, A., BENTHIN, L., & GRUNDSTROM, R. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.009 · Cited by 325
Treatment of pruritus of primary biliary cirrhosis with rifampin
Podesta, A., Lopez, P., Terg, R., Villamil, F., Flores, D., Mastai, R., Udaondo, C. B., & Companc, J. P. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01300759 · Cited by 267
Treatment of pruritus in primary biliary cirrhosis with rifampin
Ghent, C. N., & Carruthers, S. G. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90442-8 · Cited by 257
Effects of long-term rifampicin administration in primary biliary cirrhosis
Bachs, L., Parés, A., Elena, M., Piera, C., & Rodés, J. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90335-v · Cited by 235
Copple, B. L., & Li, T. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.12.007 · Cited by 235
COMPARISON OF RIFAMPICIN WITH PHENOBARBITONE FOR TREATMENT OF PRURITUS IN BILIARY CIRRHOSIS
Bachs, L., Elena, M., Parés, A., Piera, C., & Rodés, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91608-5 · Cited by 231
Tandon, P., Rowe, B. H., Vandermeer, B., & Bain, V. G. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01200.x · Cited by 176
Khurana, S., & Singh, P. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01326.x · Cited by 162
“Lack of randomization (24, 25, 29), retrospective design (26, 31), and unforeseen use of rifampin (30) led to the exclusion of six trials.”
BackgroundTrauner, M., Wagner, M., Fickert, P., & Zollner, G. (2005) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000155551.37266.26 · Cited by 164
Galteau, M. M., & Shamsa, F. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0690-3 · Cited by 166
Köhle, C., & Bock, K. W. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.05.020 · Cited by 157
The pregnane X receptor: from bench to bedside
Ma, X., Idle, J. R., & Gonzalez, F. J. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.7.895 · Cited by 161
“The benefit of rifampicin for primary biliary cirrhosis was proposed as the metabolic regulation, as shown by an increase of antipyrine clearance and the enhanced urinary excretion of 6 β -hydroxycortisol [71] .”
BackgroundHepatoprotective role of PXR activation and MRP3 in cholic acid‐induced cholestasis
Teng, S., & Piquette‐Miller, M. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707235 · Cited by 130
“One well known PXR activator, rifampicin, is used clinically for the treatment of complications associated with cholestatic diseases (Hoensch et al., 1985) and lithocholic acid-induced liver injury is attenuated by the rodent PXR activator, 5-pregnen-3b-ol-20-one-16acarbonitrile (PCN) (Staudinger…”
BackgroundPrimary biliary cirrhosis: Pathophysiology, clinical presentation and therapy
Purohit, T., & Cappell, M. S. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i7.926 · Cited by 138
Benign recurrent intrahepatic cholestasis
Luketic, V. A., & Shiffman, M. L. (2004) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00133-8 · Cited by 110
Batta, A. K., Arora, R., Salen, G., Tint, G. S., Eskreis, D., & Katz, S. (1989) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38207-9 · Cited by 112
Antipyrine as a model drug to study hepatic drug-metabolizing capacity
Poulsen, H. E., & Loft, S. H. (1988) · Journal of Hepatology · doi:10.1016/s0168-8278(88)80057-6 · Cited by 104
Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy
Geenes, V., Chambers, J., Khurana, R., Shemer, E. W., Sia, W., Mandair, D., Elias, E., Marschall, H.-U., Hague, W., & Williamson, C. (2015) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2015.03.020 · Cited by 98
Benedetti, M. S., & Dostert, P. (1994) · Environmental Health Perspectives · doi:10.1289/ehp.94102s9101 · Cited by 92
Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis
BATTA, A. K., Salen, G., Arora, R., Shefer, S., Tint, S. G., Abroon, J., Eskreis, D., & Katz, S. (1989) · Hepatology · doi:10.1002/hep.1840100404 · Cited by 90
Stimulation of bile acid 6α-hydroxylation by rifampin
Wietholtz, H., Marschall, H., Sjövall, J., & Matern, S. (1996) · Journal of Hepatology · doi:10.1016/s0168-8278(96)80268-6 · Cited by 81
Pruritus in Primary Biliary Cirrhosis: Pathogenesis and Therapy
Bergasa, N. V. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.013 · Cited by 60
Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis
Silveira, M. G., & Lindor, K. D. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.873404 · Cited by 53
“The first Phase II, multicenter, double-blind randomized controlled study was conducted in 165 patients with PBC who were non-responders to UDCA, characterized by ALP above 1.5 times upper limits of normal on appropriate therapy [45].”
BackgroundInfluentialBock, K. W., & Köhle, C. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-200033455 · Cited by 49
“Interestingly, rifampicin has been reported to relieve pruritus, possibly by reducing serum levels of bile acids (Bachs et al., 1992; Hoensch et al., 1985).”
BackgroundPruritus and fatigue in primary biliary cirrhosis
Bergasa, N. V. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00105-3 · Cited by 52
Clinical features and management of primary biliary cirrhosis
Crosignani, A. L., Battezzati, P. M., Invernizzi, P., Selmi, C. F., Prina, E., & Podda, M. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3313 · Cited by 51
Nuclear Receptors CAR and PXR; therapeutic targets for cholestatic liver disease
Kakizaki, S., Takizawa, D., Tojima, H., Horiguchi, N., Yamazaki, Y., & Mori, M. (2011) · Frontiers in bioscience · doi:10.2741/3893 · Cited by 46
“Rifampicin, PXR ligand induces the hepatic metabolism in PBC patients to ameliorate the symptoms of pruritus (93) and lower the serum concentrations of alkaline phosphatase, a marker of cholestatic liver disease, and BAs (94, 95).”
BackgroundPruritus in advanced internal diseases Pathogenesis and treatment
Krajnik, M. (2001) · The Netherlands Journal of Medicine · doi:10.1016/s0300-2977(00)00084-x · Cited by 39
BENIGN RECURRENT INTRAHEPATIC CHOLESTASIS
Luketic, V. A., & Shiffman, M. L. (1999) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70083-0 · Cited by 38
Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin
Ellis, E. C. S., Wagner, M., Lammert, F., Németh, A., Gumhold, J., Strassburg, C. P., Kylander, C., Katsika, D., Trauner, M. A., Einarsson, C., et al. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.09.011 · Cited by 35
“Bilirubin was not significantly affected in the study populations mentioned [7–13], but there was a trend towards lower levels in one long-term study [12].”
BackgroundMethodInfluentialThe Pathological Effects of Circulating Hydrophobic Bile Acids in Alzheimer’s Disease
Ehtezazi, T., Rahman, K., Davies, R., & Leach, A. G. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220071 · Cited by 41
“Rifampicin 600 mg Hydroxylation of hydrophobic bile acids and reducing their cytotoxicity 1-2 weeks Reduced total and conjugated bile acids No adverse effects [382, 383]”
BackgroundUpdate on the Treatment of the Pruritus of Cholestasis
Bergasa, N. V. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.11.009 · Cited by 35
Corpechot, C., Chen, P., Wendum, D., Matsuda, F., Barbu, V. D., & Poupon, R. Y. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00695.x · Cited by 33
“In patients with chronic cholestatic diseases, RIF improves pruritus and decreases serum concentrations of bile acids and bilirubin (8, 9).”
BackgroundThe influence of rifampin treatment on caffeine clearance in healthy man
Wietholtz, H., Zysset, T., Marschall, H., Generet, K., & Matern, S. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80263-0 · Cited by 33
PXR as the tipping point between innate immune response, microbial infections, and drug metabolism
Bautista-Olivier, C. D., & Elizondo, G. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115147 · Cited by 30
Roberts, E. A. (2003) · Wiley eBooks · doi:10.1002/9780470987049.ch4 · Cited by 28
Treatment of Primary Biliary Cirrhosis: Therapy with Choleretic and Immunosuppressive Agents
Silveira, M. G., & Lindor, K. D. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.008 · Cited by 27
“In small studies with patients who have chronic cholestatic diseases, rifampin improves pruritus [67–70] and decreases serum concentrations of bile acids [67,71], alkaline phosphatase [67,71], aminotransferases [71], and bilirubin [67].”
BackgroundDrug interactions with calcium antagonists
Kirch, W., Kleinbloesem, C. H., & Belz, G. G. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90011-p · Cited by 27
Self-citationLonsdale-Eccles, A. A., & Carmichael, A. (2003) · Drugs & Aging · doi:10.2165/00002512-200320030-00004 · Cited by 26
“Liver enzyme-inducing drugs such as phenobarbital (phenobarbitone),[109,110] flumecinol[111] and rifampicin[109,112-115] improve hepatic pruritus.”
BackgroundSimon, F. R. (1998) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70023-4 · Cited by 24
Treatment of primary biliary cirrhosis
Poupon, R. Y., & Poupon, R. E. (2000) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2000.0107 · Cited by 22
Bergasa, N. V. (2014) · CRC Press eBooks · doi:10.1201/b16573-10 · Cited by 22
Hepatic Disorders: Features and Appropriate Management
Aldersley, M. A., & O’Grady, J. G. (1995) · Drugs · doi:10.2165/00003495-199549010-00007 · Cited by 25
González, R., Cruz, A., Ferrín, G., López‐Cillero, P., Briceño, J., Gómez‐Bravo, M. Á., Rufián, S., Ruiz, F. J. P., de la Mata, M., Marín, J. J. G., et al. (2011) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1007/s00534-011-0396-3 · Cited by 23
“In fact, the induction of DME and bile acid metabolism have been successfully exploited using adequate dosage (600 mg daily for 2 weeks) of rifampicin in order to induce pruritus amelioration and reduction of alkaline phosphatase and bile acid concentration in PBC patients [13].”
BackgroundInteraction of chloramphenicol and rifampin
Kelly, H. W., Couch, R. C., Davis, R. L., Cushing, A. H., & Knott, R. (1988) · The Journal of Pediatrics · doi:10.1016/s0022-3476(88)83216-5 · Cited by 19
Bergasa, N. V. (1995) · Seminars in Dermatology · doi:10.1016/s1085-5629(05)80052-5 · Cited by 19
Current and promising therapy for primary biliary cholangitis
Gossard, A. A., & Lindor, K. D. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1601701 · Cited by 16
Lazaridis, K. N., & Lindor, K. D. (1999) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-999-0051-0 · Cited by 12
Efficacy of Treatments for Cholestatic Pruritus: A Systemic Review and Meta-analysis
Dervout, C., Boulais, N., Barnetche, T., Nousbaum, J., Brenaut, E., & Misery, L. (2022) · Acta Dermato Venereologica · doi:10.2340/actadv.v102.310 · Cited by 13
“Rifampicin is an antibiotic that is thought to function as a pregnane X receptor agonist (44, 109).”
BackgroundPrimary biliary cirrhosis in the mouse: induction by human mycoplasma-like organisms.
Johnson, L., Wirostko, E., & Wirostko, W. J. (1990) · Europe PMC (PubMed Central) · Cited by 10
Review: the treatment of primary biliary cirrhosis
Epstein, O. (1988) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1988.tb00666.x · Cited by 8
Loeffler, D. A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1368200 · Cited by 10
Rifampicin Induces Bicarbonate-Rich Choleresis in Rats: Involvement of Anion Exchanger 2
Wang, W., Ren, X., Cai, Y., Chen, L., Zhang, W., & Xu, J. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3850-2 · Cited by 5
Complications of Liver Disease
Bergasa, N. V. (2021) · Springer eBooks · doi:10.1007/978-1-4471-4715-2_15 · Cited by 4
Up-to-Date Snapshot of Current and Emerging Medical Therapies in Primary Biliary Cholangitis
Warsop, Z. I., Anand, N., Maliki, H. A., Souza, S. D., Kamyab, A. A., Hadad, A. A., & Alrubaiy, L. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14121133 · Cited by 4
Bergasa, N. V., & Jones, E. A. (1998) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70014-3 · Cited by 3
La cirrhose biliaire primitive
Grippon, P., Cadranel, J., & Opolon, P. (1988) · La Revue de Médecine Interne · doi:10.1016/s0248-8663(88)80014-6 · Cited by 2
Ripp, S. L. (2008) · Springer eBooks · doi:10.1007/978-0-387-77300-1_4 · Cited by 2
Treatment Effect of Rifampicin on Cholestasis
(2005) · The Internet Journal of Pharmacology · doi:10.5580/1bf3 · Cited by 2
Behandlungsstrategien der primär-biliären Zirrhose
Epstein, O. (1989) · Springer eBooks · doi:10.1007/978-3-642-74671-0_4 · Cited by 1
Primary Biliary Cirrhosis: Clinical Aspects
Kaplan, M. M. (1989) · Springer eBooks · doi:10.1007/978-1-4684-7041-3_14 · Cited by 1
García‐Villarreal, L., Zozaya, J., Macías, E., Garcia-Gonzalez, N., Quiroga, J. A., Conchillo, F., & Prieto, J. (1991) · PubMed · Cited by 2
Was ist gesichert in der Therapie der primär-biliären Zirrhose?
Wiedmann, K. H., Weber, P., & Lauchart, W. (1988) · Springer eBooks · doi:10.1007/978-3-662-39609-4_125
Autoimmune Liver Diseases: Primary Biliary Cholangitis
Ali, A. H., Carey, E. J., & Lindor, K. D. (2016) · Springer eBooks · doi:10.1007/978-3-319-30103-7_16
Treatment of pruritus in malignant diseases
Żylicz, Z., & Krajnik, M. (2009) · Via Medica Journals
Hopf, U., Stemerowicz, R., König, V., Küther, S., Lobeck, H., Miksits, K., & Wagner, J. (1993) · Springer eBooks · doi:10.1007/978-3-642-77930-5_24
Marschall, H., Wagner, M., Zollner, G., Fickert, P., Gumhold, J., Silbert, D., Diczfalusy, U., Benthin, L., Grundström, R., Gustafsson, U. O., et al. (2007) · Springer eBooks · doi:10.1007/1-4020-2913-6_28
Albinus, M., Amschler, G., Amschler, U., Angerer, E. V., Barthel, W., Bauer, A., Bauer, K., Beckmann, J., Beil, W., Beitz, J., et al. (1994) · Springer eBooks · doi:10.1007/978-3-642-57880-9_3
(1988) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.1988.26.8.497
Lésions hépatiques induites par l'ischémie reperfusion et la NAFLD : mécanismes et protection
Iannelli, A. (2010) · theses.fr (ABES) · doi:10.70675/701458fczea0az4a7az8d86z08f08e5f71fc
Metadata
- Authors
- Hoensch, H. P., Balzer, K., Dylewizc, P., Kirch, W., Goebell, H., & Ohnhaus, E. E.
- Affiliations
- Essen University Hospital (DE)
- ORCID
- Hoensch, H. P.
- Venue
- European Journal of Clinical Pharmacology
- Published
- 1985
- Volume
- 28
- Issue
- 4
- Pages
- 475-477
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W1972626752
- Cited by
- 76
- References
- 10
- Citations by year
- 2024: 2 · 2023: 1 · 2022: 2 · 2021: 1 · 2019: 1 · 2018: 1 · 2016: 1 · 2015: 4 · 2014: 2
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- rifampicin, primary biliary cirrhosis, drug metabolism induction, cytochrome P450, bile acids, pruritus, antipyrine clearance, alkaline phosphatase, cholestasis, hepatic metabolism
- MeSH terms
- Adult, Alkaline Phosphatase, Antipyrine, Bile Acids and Salts, Humans, Liver, Liver Cirrhosis, Biliary, Middle Aged, Rifampin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.